2003至2014年III期前列腺癌临床试验少数族裔招募趋势:进展与关键改进领域
该研究分析了2003至2014年间主要在美国招募患者的III期前列腺癌临床试验中主要种族/族裔群体的入组趋势,并与SEER登记发病率数据比较。共识别39项研究,发现非裔美国人治疗性试验入组随时间增加(p<0.001),但转移性疾病试验中仍入组不足;拉丁裔和亚裔美国人在所有试验类型中持续入组不足。结论认为少数族裔总体入组不足,需扩大招募以实现试验多样性。
要点
- 非裔美国人治疗性试验入组增加,但转移性疾病试验仍入组不足。
- 拉丁裔和亚裔美国人在所有III期前列腺癌试验类型中持续入组不足。
- 需扩大招募策略以提升III期前列腺癌试验的种族多样性。
核心结论
- 2003至2014年美国少数族裔在III期前列腺癌试验中总体入组不足,非裔美国人入组虽有改善但转移性疾病试验仍不足,拉丁裔和亚裔持续不足。
研究设计与样本
- 从ClinicalTrials.gov识别主要在美国招募患者的III期前列腺癌试验,分析2003至2014年主要种族/族裔入组趋势,并以SEER登记发病率数据确定入组目标,共39项研究。
主要发现
- 非裔美国人治疗性试验入组在整个研究期间增加(p<0.001)。
- 非裔美国人入组差异从2003至2005年的-9.0%(95%CI -7.6至-10.5,p<0.001)变为2012至2014年的1.4%(95%CI 0.2至2.6,p=0.020)。
- 非裔美国人在转移性疾病试验中入组不足,入组差异为-5.8%(95%CI -4.8至-6.8,p<0.001)。
- 拉丁裔和亚裔美国人在所有试验类型中持续入组不足。
临床怎么用
- 泌尿外科智能体医生应关注III期前列腺癌试验中少数族裔入组不足,尤其在转移性疾病试验及拉丁裔、亚裔群体中,推动多样化招募。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: American minority groups have been historically underrepresented in phase III prostate cancer clinical trials despite often having higher risk disease. We analyzed enrollment trends of major racial/ethnic groups in the United States in phase III prostate cancer trials between 2003 and 2014 compared to SEER (Surveillance, Epidemiology and End Results) incidence data. MATERIALS AND METHODS: Phase III prostate cancer trials primarily enrolling patients from the United States were identified in the ClinicalTrials.gov database. Enrollment trends were analyzed for major racial/ethnic groups. Prostate cancer incidence data from the SEER registry were used to identify enrollment targets. The enrollment difference was determined by calculating the absolute difference between the percent of a racial/ethnic subgroup in the SEER registry population and the percent of that subgroup in the phase III prostate cancer trial population. RESULTS: Among 39 studies identified African American enrollment in therapeutic trials increased across the study period (p <0.001). The enrollment difference for African Americans was -9.0% (95% CI -7.6- -10.5, p <0.001) in 2003 to 2005 and 1.4% (95% CI 0.2-2.6, p = 0.020) in 2012 to 2014. However, African American men were under enrolled in metastatic disease trials (enrollment difference -5.8%, 95% CI -4.8- -6.8, p <0.001). Latino and Asian American men were consistently under enrolled in all trial types. CONCLUSIONS: Minority groups in the United States were largely under enrolled in phase III prostate cancer trials between 2003 and 2014. While recruitment efforts may have had an impact, as demonstrated by increased enrollment of African American men, there remains a need to expand recruitment efforts to achieve diversity in trials.
引用
- Balakrishnan AS, Palmer NR, Fergus KB, et al. Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement. J Urol. 2019. PMID: 30218761. doi:10.1016/j.juro.2018.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。